MAOB and Parkinson disease: Safinamide ((2S)-2-[[4-[(3-fluorophenyl) methoxy] phenyl] methylamino] propanamide), used to clinically treat Parkinson’s disease (PD), is a novel, reversible, and highly selective monoamine oxidase B (MAO-B) inhibitor (Fariello et al., 1998; Maj et al., 1998; Maj et al., 1999; Muller, 2017; Hattori et al., 2020; Müller, 2020; Rinaldi et al., 2021; Stocchi et al., 2021).